Ernexa Therapeutics ERNA
NASDAQ ERNA
$4.86 +0.25 (+5.31%)
At close: Aug 21, 2026 · 4:00 PM EDT

Ernexa Therapeutics Inc. (ERNA) Non-Current Deferred Tax Liability (2012 - 2017)

Ernexa Therapeutics' (ERNA) quarterly Non-Current Deferred Tax Liability came in at $52000.0 in Q4 2017, up 6.12% YoY from $49000.0 in Q4 2016, and up 6.12% on a QoQ basis from $49000.0 in Q4 2016.

Ernexa Therapeutics Inc. (ERNA) Non-Current Deferred Tax Liability (2012 - 2017) Analysis & Trends

Ernexa Therapeutics (ERNA) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $52000.0 in Q4 2017.

  • Quarterly Non-Current Deferred Tax Liability rose 6.12% year-over-year to $52000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $52000.0 (up 6.12% YoY) and the FY2017 annual result came in at $52000.0, up 6.12% from the prior year.
  • Non-Current Deferred Tax Liability improved to $52000.0 in Q4 2017, from $49000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $52000.0 in Q4 2017 to a low of -$11000.0 in Q4 2013.
  • A 3-year average of $30000.0 and a median of $49000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2013 — Non-Current Deferred Tax Liability jumped 85.9% — and 2017, when it grew 6.12%.
  • Tracing ERNA's Non-Current Deferred Tax Liability over 3 years: stood at -$11000.0 in 2013, then jumped by 545.45% to $49000.0 in 2016, then rose by 6.12% to $52000.0 in 2017.
  • The last three Non-Current Deferred Tax Liability figures came in at $52000.0 (Q4 2017), $49000.0 (Q4 2016), and -$11000.0 (Q4 2013), per Business Quant data.

Peer Comparison

Historic Data

Download Data
DateValue
Dec 31, 2017 52,000.00
Dec 31, 2017 52,000.00
Dec 31, 2016 49,000.00
Dec 31, 2016 49,000.00
Dec 31, 2013 -11,000.00
Dec 31, 2013 -11,000.00
Dec 31, 2012 -78,000.00
Dec 31, 2012 -78,000.00